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Abstract
Complicated skin and soft tissue infections (cSSTI) are common and frequently require treatment in hospital. Comprehensive current data on
management practices in patients hospitalized with cSSTI are limited. REACH was a retrospective, observational cohort study designed to
provide data on current clinical management of moderate to severe cSSTI in European hospitals. Data were collected via an electronic case
report form from 129 sites in ten European countries. The study population comprised patients  18 years, hospitalized betweenMarch 2010
and February 2011 with cSSTI who received intravenous antibiotic treatment. Presented here is an analysis of the disease characteristics,
treatment patterns during hospitalization and clinical outcomes identiﬁed by the study. The total population included 1995 patients (mean age
60.6 years; 57.7% male). Initial antibiotic treatment modiﬁcation was reported in 39.6% (n = 791) of patients; it was more common in patients
with co-morbidities (42.6%), those requiring surgical intervention (43.4%), those with more severe infections such as bacteraemia (51.6%) or
with fascia affected (49.0%), those admitted to the intensive care unit (56.2%) and those with lesions > 50 cm2 (44.3%). A switch to narrower-
spectrum antibiotic treatment (streamlining) occurred in 5.6% of patients. Mean length of hospital stay was 18.5 days (19.9; median 12.0) and
the total mortality rate was 3.4%. The data collected in REACH give a comprehensive and current view of real-life clinical management of cSSTI
in European hospitals and provide evidence of a high rate of initial antibiotic treatment modiﬁcation.
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Introduction
Complicated skin and soft tissue infections (cSSTI), also
termed ‘acute bacterial skin and soft tissue infections’ by the
US Food and Drug Administration, are among the most
common infections treated in the hospital setting. They
represent a heterogeneous range of diseases, from patients
with severe infection who are otherwise healthy to patients
with relatively minor infection but underlying co-morbidities
[1]. Some of these infections involve deep layers of skin and
supporting structures, leading to substantial morbidity and
mortality that can be resource intensive and incur high
healthcare costs [2, 3]. Patients frequently receive intravenous
(IV) antibiotic therapy and surgical intervention [2, 4], and
treatment may be further complicated by the presence of
signiﬁcant co-morbidities such as immunological disorders and
diabetes mellitus [4–6].
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Common examples of cSSTI include abscesses, cellulitis,
fasciitis, diabetic foot infections and post-trauma and surgical
site infections [7], as well as superﬁcial infections or abscesses
in an anatomical site where the risk of anaerobic or Gram-
negative pathogen involvement is high, such as the rectal area
[1, 8]. cSSTI may be polymicrobial and may involve both
aerobic and anaerobic, and Gram-positive and Gram-negative,
pathogens [9].
The predominant pathogens causing cSSTI are aerobic
Gram-positive cocci, speciﬁcally Staphylococcus aureus, and
streptococci [6]. S. aureus was isolated from 44.6% of North
American patients with cSSTI over a 7-year period (1998–
2004) [10]. A number of other pathogens are linked with cSSTI
in speciﬁc epidemiological or clinical situations, most notably
anaerobes and Gram-negative bacilli in patients with diabetes
mellitus, and Pseudomonas aeruginosa in patients with neutro-
penia [6]. The emerging incidence of resistance to multiple
antibiotics in bacteria makes cSSTI increasingly challenging to
treat [11]. Furthermore, the choice of treatment is often
complicated by the need to treat without a conﬁrmed
microbiological diagnosis.
cSSTI are reported to account for up to 10% of admissions
to infection units in the USA [12] and in the United Kingdom
[13]. However, cSSTI are complex to categorize as no clear
deﬁnitions of severity are available, making it difﬁcult to reach
consistent decisions regarding which infections require hospi-
talization.
Information about real-life management of cSSTI, identiﬁ-
cation of risk factors for initial antibiotic treatment modiﬁca-
tion and its impact is limited. The REtrospective Study to
Assess the Clinical Management of Patients with Moderate-to-
Severe cSSTI or Community-Acquired Pneumonia (CAP)
Infections in the Hospital Setting (REACH; NCT01293435)
was a collaboration involving independent experts in cSSTI and
CAP, a health economist and clinical investigators across
Europe. The primary objective of the study was to systemat-
ically collect new, current (2010–2011) pan-European data on
patients hospitalized with cSSTI or CAP to create a better
understanding of patient and disease characteristics, and
current clinical management in response to the real-world
challenges of treating these infections.
Methods
REACH was a multinational, multicentre, observational,
retrospective cohort study of patients hospitalized with cSSTI
and CAP. Only cSSTI patients are included in this analysis.
Data were collected from 129 sites in ten participating
European countries (see Appendix S1 for full list of investiga-
tors). A variety of hospitals were included in the study,
including university-afﬁliated, general, regional, public, private
and large, medium and small hospitals.
The study was performed according to Good Clinical
Practice and the Declaration of Helsinki. All local ethics
committees approved the study protocol. Local legislation
relating to written informed consent for non-interventional
studies was followed in each country; in Germany and
Portugal, where this information is mandatory, written
informed consent was collected.
FIG. 1. Patient ﬂow. *For example,
patients assigned a patient number
but eCRF not completed before
database lock.
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Patients
The study population comprised patients diagnosed with cSSTI
hospitalized between December 2010 and January 2011. The
identiﬁcation period was extended to include November 2010
and February 2011 and then extended backwards, month by
month, until sufﬁcient numbers of patients were obtained, or
until March 2010, whichever was reached ﬁrst.
Inclusion and exclusion criteria. Adults aged  18 years, hospi-
talized with cSSTI and receiving treatment with IV antimicro-
bials were included in the analysis population. Patients were
selected from the total number of patients admitted to
hospital within that time frame with cSSTI, as identiﬁed by
World Health Organization ICD-10 diagnostic codes [14],
using an automatic randomization tool. The selected patients
were then assessed for eligibility by conducting a ﬁrst review of
the medical charts. Patients who did not meet the predeﬁned
criteria of cSSTI (detailed in Data S1) or who did not require
IV antibiotics were excluded. The rest were enrolled (Fig. 1).
Further inclusion and exclusion criteria are detailed in Data S1.
Study variables
Variables collected and measured by completion of an
electronic case report form are detailed in Data S1.
Data analysis
This was a retrospective non-interventional study, using a
descriptive analysis approach to assess clinical management
and clinical outcomes. All calculations and summaries were
produced using SAS Version 9.2.
‘Initial antibiotic treatment modiﬁcation’ was deﬁned as the
need for a change in initial antibiotic treatment due to insufﬁcient
response, adverse reaction, interaction with other drugs, non-
suitability of the initial antibiotic based on the results of
microbiological tests, or changes to antibiotic therapy or
addition of further agents, alone or in combination. Cases of
‘streamlining’, deﬁned as change to narrower-spectrum antibi-
otics upon patient improvement or conﬁrmed microbiological
diagnosis, were recorded separately. Cases of patient death
while on initial antibiotic treatment were also recorded.
Results
Patient population
Patients (N = 1995) were enrolled between March 2010 and
February 2011 (the majority between October 2010 and
February 2011; Fig. 1, Table S1, Data S1).
The mean age of patients was 60.6 years; 45.2% (n = 902) of
patients were  65 years old and 57.7% (n = 1152) were male.
There was a high degree of co-morbidity, with 78.0% (n = 1556)
of patients reporting one ormore conditions, themost common
being diabetes mellitus. The mean age of patients with co-
morbidities was higher than for patients without (63.8  16.0
vs. 49.3  18.6 years, respectively; Table 1).
Disease characteristics, including types of infectious lesions,
recurrences, nosocomial infections and pretreatment with
antibiotics, are shown in Table 2. Bacteraemia was diagnosed
in 6.3% (n = 126) of the total number of patients. This
represents 11.9% of the 1058 patients who had blood cultures
performed.
Diagnostic information. All patients underwent a microbiological
test; 53.0% (n = 1058) had a blood culture and 48.6%
(n = 970) had a superﬁcial swab and culture (Table S2). A
microbiological diagnosis was obtained for 1001 (50.2%)
patients (Table 3).
Of the patients with a microbiological diagnosis, 70.1%
(n = 702) were diagnosed with infection with Gram-positive
cocci, with staphylococci accounting for 49.5% (n = 495).
TABLE 1. Patient demographics, characteristics and medical
history
Characteristics N = 1995
Male, n (%) 1152 (57.7)
Age, years, mean (SD ) [median]
 65 years, n (%)
60.6 (17.6) [62.0]
902 (45.2)
Ethnic origin, n (%)
White 1596 (80.0)
Non-white 51 (2.6)
Unknown/missing 136 (6.8)
Not applicablea 212 (10.6)
Invasive surgical treatment in the 3 months prior to initial
visit,b n (%)
279 (14.0)
Hospitalization in the previous 3 months for any reason,
n (%)
418 (20.9)
Time since previous date of hospitalization (n = 377), days,
mean (SD ) [median]
35.7 (26.9) [30.0]
Co-morbidities, any relevant condition,c n (%) 1556 (78.0)
Diabetes 676 (33.9)
Peripheral vascular disease 422 (21.2)
Congestive heart disease 244 (12.2)
Cancer/malignancy 207 (10.4)
Renal disease 196 (9.8)
Respiratory disease 190 (9.5)
Liver disease 113 (5.7)
Alcohol abuse 80 (4.0)
Immune system impairment 69 (3.5)
Injection drug use 46 (2.3)
AIDS-HIV 31 (1.6)
Infectious diseases 20 (1.0)
Other relevant conditionsc 670 (33.6)
Unknown 7 (0.4)
Medication in the 3 months prior to hospitalization, n (%) 1284 (64.3)
Antibiotics/antivirals 596 (29.9)
Anticoagulants 383 (19.2)
Non-steroidal anti-inﬂammatory drugs 179 (9.0)
Immunosuppressors/immunomodulators 130 (6.5)
Any other relevant medication 380 (19.0)
Unknown 127 (6.4)
SD , standard deviation.
aAll patients in this category were from France, where this question is not
permitted in clinical studies.
bVisit to hospital for current infection or date of diagnosis of infection for patients
already hospitalized.
cAs deﬁned by the investigator.
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Polymicrobial infections were identiﬁed in 30.2% (n = 302) of
patients.
Staphylococci were identiﬁed in 53.2% (n = 67) of patients
with bacteraemia and a microbiological diagnosis (n = 126).
Clinical management
Hospital types and specialists treating patients are shown in
Table S3.
Most patients (77.8%; n = 1553) were treated with an IV
antibiotic on the ﬁrst day of hospitalization. Empirical therapy
was received by 81.6% (n = 1628) of patients and 17.3%
(n = 346) received speciﬁc therapy directed by microbiological
diagnosis (Table S3). Surgery was required by 37% (n = 739) of
patients, 26.7% (n = 197) of whom underwent more than one
surgical intervention.
Clinical outcomes
Clinical outcomes for the full analysis population are detailed in
Table 4. Initial antibiotic treatment modiﬁcation, for any
reason, was reported in 39.6% (n = 791) of patients. Stream-
lining of treatment occurred in 5.6% (n = 111) of patients.
A number of cases listed as ‘Other’, ‘Unknown’ and ‘No
reason reported’ were reviewed case-by-case by the investi-
gators and were not related to clinical improvement, the
availability of a microbiological diagnosis or narrowing of
antibiotic spectrum. The time to treatment modiﬁcation was
< 4 days in 31.3% (n = 124) of patients,  4 days in 68.4%
(n = 271) and unknown in 0.3% (n = 1).
Mean time to ﬁrst treatment modiﬁcation (including
streamlining) was 7.7 days (8.0; median 6.0) and the total
mortality rate was 3.4% (n = 68) for the full population (7.3%
of patients with initial antibiotic treatment modiﬁcation).
Clinical stability, deﬁned by the switch from IV to oral therapy
or any other possible criteria, was reached in < 4 days by 382
(19.2%) patients (Fig. 2), although the largest number of
patients (n = 188) reached clinical stability on the fourth day of
treatment, with a mean time to clinical stability of 9.7 days
(11.2; median 7.0 days).
The mean length of hospital stay was 18.5 days (19.9;
median 12.0). Patients admitted to an intensive care unit (ICU)
(6.5%; n = 130) had a mean length of ICU stay of 9.7 days
(13.5; median 4.5 days). Home-based care after discharge
was required by 14.1% (n = 281) of patients [mean duration
26.9 days (27.2; median 15.0)].
Clinical failure (deﬁned as acute haemodynamic deteriora-
tion or death, or any other criterion considered indicative of
clinical failure) occurred in 12.5% (n = 250) of patients. Of
these, the failure was related to the cSSTI in 62.4% (n = 156)
of patients, unrelated in 22.4% (n = 56) of cases and due to
unknown reasons in 15.2% (n = 38) of cases.
Antibiotics used and outcomes. During treatment, 54 different
antibiotic agents were used as monotherapy or in combina-
tions. The antibiotics most commonly used as monotherapy
for initial and subsequent lines of treatment, and their
modiﬁcation rates, are shown in Table S4.
Analysing treatments by antibiotic classes, used as mono-
therapy or in combination with any other agent/s, revealed
that, overall, 60.3% of patients received a penicillin or penicillin
plus b-lactamase inhibitor combination as their initial antibiotic
coverage. Analysis of anti-methicillin-resistant S. aureus
(MRSA) agents used as initial monotherapy or in combination
with other antibiotics revealed that 5.2% (n = 103) of patients
received vancomycin, 4.4% (n = 87) received daptomycin and
1.9% (n = 37) received linezolid. Teicoplanin and tigecycline
were less commonly used. Patients receiving some anti-MRSA
agents experienced high rates of initial treatment modiﬁcation
(Table S4).
Clinical outcomes according to disease characteristics. Clinical
outcomes according to disease characteristics are detailed in
TABLE 2. Disease characteristics of full population
Characteristics
n (%)
N = 1995
Type of lesiona
Cellulitis/fasciitis 1179 (59.1)
Abscess 461 (23.1)
Post-surgical wound 252 (12.6)
Diabetic leg ulcer 237 (11.9)
Peripheral vascular disease ulcer 221 (11.1)
Post-traumatic wound 178 (8.9)
Decubitus ulcer 92 (4.6)
Bite 27 (1.4)
Burn 10 (0.5)
Unknown 20 (1.0)
Systemic signs of cSSTI at diagnosis
White blood cell count >10 000/mm3 1466 (73.5)
Temperature >38°C 1208 (60.5)
Immature neutrophils >10% 205 (10.3)
Organ dysfunction 129 (6.5)
Septic shock 71 (3.6)
Unknown 122 (6.1)
Recurrent skin infection episodeb 509 (25.5)
Nosocomial infection 199 (10.0)
Treatment with antibiotics before initial visitc 701 (35.1)
Penicillin/combined with b-lactamase inhibitor 348 (17.4)
Fluoroquinolone 156 (7.8)
Cephalosporin 80 (4.0)
Macrolide 40 (2.0)
Aminoglycoside 26 (1.3)
Glycopeptide 20 (1.0)
Carbapenem 19 (1.0)
Sulphonamide 8 (0.4)
Drug against mycobacteria 1 (0.1)
Other 118 (5.9)
Unknown 51 (2.6)
Co-medications during treatment 1334 (66.9)
Anticoagulants 772 (38.7)
Non-steroidal anti-inﬂammatory drugs 411 (20.6)
Immunosuppressors/immunomodulators 113 (5.7)
Chemotherapeutic agents 21 (1.1)
Any other medication 470 (23.5)
Unknown 38 (1.9)
aPatients could be classiﬁed with more than one type of cSSTI lesion.
bPatients hospitalized again due to same cSSTI.
cVisit to hospital for current infection or date of diagnosis of infection for patients
already hospitalized.
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Table 5. Patients with co-morbidities experienced a numeri-
cally higher rate of initial antibiotic treatment modiﬁcation than
those without (42.6% vs. 29.2%), greater reinfection or
recurrence (9.6% vs. 5.2%), a longer time to clinical stability
(mean 10.4 days vs. 7.1 days), a longer hospital stay (mean
19.9 days vs. 13.3 days) and a higher mortality rate (4.0% vs.
1.1%).
Patients with a nosocomial infection (10.0%; n = 199) had a
numerically longer hospital stay (mean 35.7 days vs.
16.4 days), a higher rate of initial antibiotic treatment mod-
iﬁcation (48.7% vs. 38.6%) a higher mortality rate (4.0% vs.
3.3%), and were more likely to be infected with a Gram-
negative bacterium compared with those with a non-nosoco-
mial infection (49.7% vs. 31.3%). Additionally, a higher
percentage had MRSA (13.2% vs. 9.6%). Of the patients with
a nosocomial S. aureus infection, nearly half (47.6%) had MRSA,
compared with 24% of those with non-nosocomial S. aureus
infection.
Of the 1995 patients hospitalized for cSSTI, 172 (8.6%)
patients had recurrences after discharge. These patients
presented with similar types of lesions to those patients
without a recurrent infection, although a higher percentage
had diabetic leg ulcer (22.1% vs. 10.5%) or peripheral vascular
disease ulcer (20.3% vs. 8.9%).
TABLE 4. Clinical outcomes for the full analysis population
Clinical outcome N = 1995
Initial antibiotic treatment
modiﬁcation, streamlining removed,a n (%)
791 (39.6)
Streamlining,b n (%) 111 (5.6)
Primary reason for initial antibiotic treatment modiﬁcation,c n (%)
Insufﬁcient response/treatment failure 339 (17.0)
Adverse events 55 (2.8)
Possible interaction with other treatment 1 (0.1)
Other 246 (12.3)
Unknown 68 (3.4)
No reason reported 82 (4.1)
Overall treatment duration (n = 1974), days, mean (SD )
[median]
14.6 (14.3) [11.0]
Treatment response, days, mean (SD ) [median]
Time to clinical stability (n = 1715) 9.7 (11.2) [7.0]
Based on switch from IV to oral therapy (n = 1149) 9.9 (11.6) [7.0)
Based on other criteria (n = 567) 9.2 (10.4) [6.0]
Length of hospital stay (n = 1942), days, mean (SD )
[median]
18.5 (19.9) [12.0]
Discharged from hospital, n (%) 1880 (94.2)
Reinfection or recurrence,d n (%) 172 (8.6)
Home-based care after discharge, n (%) 281 (14.1)
Length of home-based care
(n = 138), days, mean (SD ) [median]
26.9 (27.2) [15.0]
Death while on initial therapy 28 (1.4)
Total mortality rate, n (%) 68 (3.4)
IV, intravenous; SD , standard deviation.
aSeveral antibiotic treatment modiﬁcations in the same patient were counted as a
single initial antibiotic treatment modiﬁcation case. Changes in dose or frequency
of an existing antibiotic (considered as dose escalation or adjustment) and removal
of an antibiotic from a combination and adjustment of dose or frequency of the
remaining antibiotic were not considered as initial antibiotic treatment modiﬁca-
tion.
bDe-escalation of treatment to narrower-spectrum antibiotics upon patient
improvement or conﬁrmed microbiological diagnosis.
cIf multiple reasons are reported, the more clinically relevant reasons were
selected ﬁrst as the primary reason for change.
dPatients hospitalized again due to same cSSTI.
TABLE 3. Microbiological diagnosis for patients with cSSTI and bacteraemia and for patients with initial antibiotic treatment
modiﬁcation
Patients with a
microbiological
diagnosis
n = 1001
Patients with
initial antibiotic
treatment
modiﬁcation
n = 493
Patients with
bacteraemia and
a microbiological
diagnosis
n = 126
Patients with
bacteraemia and
initial antibiotic
treatment
modiﬁcation
n = 64
Microbiological diagnosis n (%) n (%) n (%) n (%)
Gram-positive coccia 702 (70.1) 351 (71.2) 97 (77.0) 51 (79.7)
Methicillin-sensitive Staphylococcus aureus 279 (27.9) 116 (23.5) 32 (25.4) 14 (21.9)
Methicillin-resistant Staphylococcus aureus 102 (10.2) 58 (11.8) 17 (13.5) 12 (18.8)
Coagulase-negative Staphylococcus 112 (11.2) 59 (12.0) 17 (13.5) 8 (12.5)
Vancomycin-intermediate S. aureus (VISA) 2 (0.2) 2 (0.4) 1 (0.8) 1 (1.6)
Streptococcus pyogenes (group A b-haemolytic streptococci) 40 (4.0) 21 (4.3) 11 (8.7) 7 (10.9)
Streptococcus agalactiae (group B b-haemolytic streptococci) 32 (3.2) 16 (3.2) 7 (5.6) 3 (4.7)
Other b-haemolytic streptococcib 66 (6.6) 34 (6.9) 10 (7.9) 6 (9.4)
Streptococcus pneumoniae 4 (0.4) 1 (0.2) 4 (3.2) 1 (1.6)
Enterococcus faecalis 85 (8.5) 58 (11.8) 7 (5.6) 5 (7.8)
Enterococcus faecium 29 (2.9) 18 (3.7) 5 (4.0) 4 (6.3)
Other Gram-positive bacteriac 33 (3.3) 21 (4.3) 1 (0.8) 1 (1.6)
Enterobacteriaceaed 341 (34.1) 193 (39.1) 26 (20.6) 15 (23.4)
Non-fermenting Gram-negative bacillie 112 (11.2) 65 (13.2) 9 (7.1) 4 (6.3)
Other Gram-negative bacteriaf 4 (0.4) 3 (0.6) 0 0
Strict anaerobic bacteriag 34 (3.4) 15 (3.0) 4 (3.2) 1 (1.6)
Yeasts 14 (1.4) 11 (2.2) 1 (0.8) 1 (1.6)
Other microorganisms 34 (3.4) 9 (1.8) 1 (0.8) 1 (1.6)
Unknown diagnosis 999 (50.1) 301 (38.1) 0 0
aIncludes Staphylococcus warnerii, Staphylococcus lugdugensis, Staphylococcus haemolyticus, Staphylococcus epidermidis, Staphylococcus spp. non-aureus, Streptococcus mitis, Streptococcus
constellatus, viridans Streptococcus, Group G streptococci, Streptococcus mitis, Enterococcus spp., unspeciﬁed Gram-positive cocci.
bIncludes S. dysgalactiae, Group C streptococci, microaerophilic streptococci, S. mileri, S. intermedius, S. anginosus, S. bovis.
cIncludes Bacillus anthracis, Corynebacterium spp., diphtheroids, Proprionibacterium spp., Lactobacillus spp., Clostridium spp., Gram-positive bacilli non-speciﬁed.
dIncludes Proteus mirabilis, Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter spp., Serratia marcescens, Providencia stuartii, Morganella morganii, Pantoea spp.).
eIncludes Pseudomonas spp., Acinetobacter spp., Stenotrophomonas maltophilia, Shewanella putrefaciens.
fIncludes Neisseria spp., Aeromonas hydrophila, Pasteurella multocida.
gIncludes Gemella morbillorum, Bacteroides fragilis, Peptostreptococcus spp., Prevotella melaninogenica, Porphyromonas spp.
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Clinical outcomes in some speciﬁc cSSTI patient groups and
by site of infection are shown in Table 5. Initial antibiotic
treatment modiﬁcation rate was numerically higher, compared
with the total population, in patients with more severe
infections, such as patients with bacteraemia (51.6%), patients
admitted to the ICU (56.2%), patients with lesions > 50 cm2
(44.3%) and patients with fascia affected (49.0%). Of the
patients with fascia affected, 65.9% (n = 284) required surgery
and 73.5% (n = 317) had a microbiological diagnosis, 40.4%
(n = 128) of which were mixed infections with two or more
microorganisms identiﬁed. Patients with fascia affected and
patients admitted to the ICU had longer hospital stays (mean
26.8 and 37.1 days, respectively), longer time to clinical
stability (mean 15.7 and 16.8 days, respectively) and a higher
rate of mortality (7.0% and 16.9%, respectively). Patients
 65 years old had a numerically higher mortality rate than
younger patients (5.5%; n = 50 vs. 1.6%; n = 18). Patients with
a conﬁrmed diagnosis of MRSA had a high requirement for
FIG. 2. Distribution of patients
according to time to clinical stability.
TABLE 5. Clinical outcome according to disease characteristics, in speciﬁc cSSTI patient groups and by site of infection
Initial antibiotic
treatment
modiﬁcation,
n (%)
Streamlining,
n (%)
Reinfection
or recurrence,a
n (%)
Length of hospital
stay,b days, mean
(SD ) [median]
Time to clinical
stability,c days,
mean (SD )
[median]
Total
mortality
rate, n (%)
Full analysis population,
N = 1995
791 (39.6) 111 (5.6) 172 (8.6) 18.5 (19.9) [12.0]
(n = 1942)
9.7 (11.2) [7.0]
(n = 1715)
68 (3.4)
With co-morbidities,
n = 1556
663 (42.6) 78 (5.0) 149 (9.6) 19.9 (20.4) [14.0]
(n = 1514)
10.4 (11.7) [7.0]
(n = 1340)
63 (4.0)
Without co-morbidities,
n = 439
128 (29.2) 33 (7.5) 23 (5.2) 13.3 (16.9) [8.0]
(n = 428)
7.1 (8.8) [5.0]
(n = 375)
5 (1.1)
Nosocomial cSSTI,
n = 199
97 (48.7) 8 (4.3) 13 (6.5) 24.0 (23.3) [16.0]
(n = 193)
11.2 (11.2) [8.0]
(n = 153)
8 (4.0)
Non-nosocomial cSSTI,
n = 1796
694 (38.6) 103 (5.8) 159 (8.8) 16.4 (17.5) [11.0]
(n = 1749)
9.5 (11.2) [7.0]
(n = 1562)
60 (3.3)
With recurrence,a
n = 172
70 (40.7) 11 (6.4) 172 (100.0) 35.7 (27.5) [29.0]
(n = 172)
12.3 (14.2) [7.0]
(n = 145)
0 (0.0)
Without recurrence,a
n = 1563
611 (39.1) 91 (5.8) 0 16.4 (17.5) [11.0]
(n = 1562)
9.2 (10.9) [6.0]
(n = 1404)
1 (0.1)
With NSAIDs,
n = 411
186 (45.3) 31 (7.5) 50 (12.2) 18.9 (17.7) [13.0]
(n = 407)
10.0 (11.16) [7.0]
(n = 355)
8 (1.9)
Without NSAIDs,
n = 1584
605 (38.2) 80 (5.0) 122 (7.7) 18.3 (20.4) [12.0]
(n = 1535)
9.6 (11.3) [7.0]
(n = 1360)
60 (3.8)
With surgical intervention,
n = 739
321 (43.4) 54 (7.3) 91 (12.3) 24.4 (26.0) [16.0]
(n = 713)
12.8 (15.5) [8.0]
(n = 631)
31 (4.2)
Without surgical intervention,
n = 1238
467 (37.7) 57 (4.6) 81 (6.5) 15.0 (14.2) [11.0]
(n = 1221)
7.8 (7.1) [6.0]
(n = 1082)
37 (3.0)
Patients with bacteraemia,
n = 126
65 (51.6) 14 (11.1) 13 (10.3) 26.6 (26.4) [16.0]
(n = 118)
13.0 (14.8) [10.0]
(n = 110)
5 (4.0)
Patients with fascia affected,
n = 431
211 (49.0) 22 (5.1) 59 (13.7) 26.8 (26.3) [18]
(n = 416)
15.7 (17.6) [11.0]
(n = 355)
30 (7.0)
Lesion extension 10–50 cm2,
n = 504
220 (43.7) 22 (4.4) 48 (9.5) 17.8 (20.5) [12.0]
(n = 488)
9.1 (8.9) [6.0]
(n = 450)
14 (2.8)
Lesion extension >50 cm2,
n = 318
141 (44.3) 29 (9.2) 22 (6.9) 18.3 (21.6) [11.0]
(n = 314)
8.3 (8.4) [6.0]
(n = 286)
17 (5.3)
Patients admitted to ICU,
n = 130
73 (56.2) 10 (7.7) 16 (12.3) 37.1 (35.5) [25.0]
(n = 123)
16.8 (15.2) [14.0]
(n = 92)
22 (16.9)
Patients not admitted to ICU,
n = 1844
715 (38.8) 101 (5.5) 156 (8.5) 15.8 (15.6) [11.0]
(n = 1810)
9.3 (10.8) [7.0]
(n = 1619)
46 (2.5)
NSAIDs, non-steroidal anti-inﬂammatory drugs; SD , standard deviation.
aPatient hospitalized again due to same cSSTI.
bIncludes duration of all hospitalizations for patients with recurrences. In cases of nosocomial infection, length of hospital stay was calculated starting on the date of cSSTI diagnosis.
cBased on switch from IV to oral therapy or any other possible criteria.
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initial treatment modiﬁcation (56.9%; n = 58), while that for
patients with methicillin-sensitive S. aureus (MSSA) was 41.4%
(n = 116). The characteristics of patients requiring initial
antibiotic treatment modiﬁcation and their disease character-
istics are presented in Tables S5 and S6.
Discussion
The real-world evidence collected in the REACH study
revealed unexpectedly high ﬁrst-line treatment modiﬁcation
rates in hospitalized cSSTI patients throughout Europe.
The patient population described in this study was similar to
that of previous studies [15, 16], being composed of older adults
(45.2%  65 years of age), with a high degree of co-morbidity
and concurrent treatment with medications, including antibiot-
ics and antivirals. However, the patients in this study may have
had more severe infections, as a high percentage had fever,
leukocytosis and bacteraemia, which may be due to the
enrollment criteria selected. The impact of co-morbidities on
clinical outcomes for patients was considerable, increasing the
risk of initial antibiotic treatment modiﬁcation, reinfection or
recurrence, length of hospital stay and death. The types of
infection encountered were similar to those seen in other
studies, including abscesses, cellulitis/fasciitis, infected ulcers in
patients with diabetes or peripheral vascular disease, and
postoperative and traumatic wound infections [15, 17].
Diagnosis of a cSSTI is generally based on clinical criteria
and treatment is usually initiated before a microbiological
diagnosis is available. Therefore, the antibiotic choice initially
depends on the type and severity of infection and the
suspected pathogens. Hence, although all patients in this study
underwent a microbiological test, only half had a microbio-
logical diagnosis. Swabs, notoriously unreliable diagnostic
tools, were used in almost half of all tests. Thus, the majority
was treated empirically. The fact that swabs are used so often
indicates that there is considerable room for improvement in
the way microbiological diagnosis is carried out in routine
practice in cSSTI; real-life studies are useful to unveil this type
of information. Conversely, the number of blood cultures
performed and the percentage of positive cultures was higher
than reported by others [18, 19]. Bacteraemia is uncommon in
cellulitis: among 272 patients, initial blood cultures were
positive in 4% of patients [19]. Blood cultures produce a low
yield, with less than 5% of cases being positive [18]. The
incidence of bacteraemia in our study was high, at 6.3%, and
mortality in this group of patients was also high at 4%. The
incidence of bacteraemia in controlled trials for new antibiotic
agents for the treatment of cSSTI has been reported to range
from 1–5% and mortality in these patients ranged from 0–1.5%
[20–22]. This indicates that patients in the real-life REACH
study had more severe illness than the populations recruited
into controlled trials. The decision-making process in cSSTI
across European hospitals requires consideration of a broad
range of potential pathogens and often the need to treat
without a conﬁrmed microbiological diagnosis. The lack of
recent European treatment guidelines in cSSTI, together with a
choice from a large generic pool of treatment options, may
partly account for the high percentage of initial treatment
modiﬁcations recorded in all countries. Thus, improved
antimicrobial stewardship may be necessary, as well as
initiatives to improve empirical treatment strategies and
develop clear guidelines.
Recently, the US Food and Drug Administration explored
the use of ‘early clinical response’ to antimicrobial therapy on
Day 3 (for cSSTI) as an efﬁcacy endpoint in clinical trials [23].
This endpoint was based on historical data, which indicated
that the greatest antimicrobial treatment effect in controlled
studies was after approximately 48–72 hours of antibiotic
therapy. Data obtained from REACH (Fig. 2) indicate high
levels of early response, with the peak number of patients
reported achieving clinical stability at Day 4.
The most common organisms identiﬁed in cSSTI infections
in this study were Gram-positive cocci (70.1%), the majority of
which were S. aureus, which is in concordance with the
ﬁndings of other studies [10, 15]. MRSA incidence in cSSTI is
known to vary considerably between countries, although the
10.2% of all microbiological diagnoses in this study appears low
and at odds with other published studies reporting ranges
from 22.8% in Europe to 59% in the USA [10, 15, 24, 25]. This
variation may be partly explained by the majority of patients in
REACH having community-onset infections where MRSA is
rarely found in Europe, compared with nosocomial infections
where MRSA is more frequently involved.
The rate of initial antibiotic treatment modiﬁcation was
high, particularly in certain groups of patients, such as those
with co-morbidities, those with a recurrent or nosocomial
infection, patients requiring surgical intervention, those taking
non-steroidal anti-inﬂammatory drugs or patients with more
severe infections. It is difﬁcult to make comparisons across
studies as deﬁnitions of treatment modiﬁcation may differ;
however, this initial antibiotic treatment modiﬁcation rate is
higher than has been reported previously (22–23%) [17, 26],
but reﬂects current treatment and outcomes. Recommended
treatment guidelines for cSSTI provide very little consensus on
initial antibiotic choice and include a wide variety of antibiotic
therapies dependent on the type and site of infection, its
severity and local knowledge concerning possible antibiotic
resistance [6, 7, 9]. The large variability in antibiotic
treatments and high rate of antibiotic treatment modiﬁcations
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in REACH, frequently within 4 days (before any reasonable
time frame to assess the response to treatment has elapsed),
suggests that the antibiotic treatment was modiﬁed in some
cases on transfer of the patient from the emergency depart-
ment to the general ward, with no reason speciﬁed. However,
17% of patients had initial treatment modiﬁcation due to
conﬁrmed insufﬁcient response, agreeing with previous
reports for similar patients [15], as well as with a recent
study reporting inappropriate initial antibiotic therapy in 18.5%
of patients with a microbiological diagnosis [25] and an
association with signiﬁcantly worse clinical and economic
outcomes [17]. A health economic analysis of our study
showed an association between initial antibiotic treatment
modiﬁcation and higher use of resources (H. Ostermann,
personal communication). If these results are to be taken as a
true picture of the need for initial antibiotic treatment
modiﬁcation in cSSTI in Europe, then a reassessment of the
current approaches to antibiotic prescribing is recommended
to increase the success of initial antibiotic use, especially in the
more vulnerable patient groups.
A possible limitation of the study was the notable differences
in patient recruitment processes in the different countries,
mostly due to differences in ethical committee requirements,
which led to differences in the numbers of patients recruited
from each country. Because of its retrospective design, there
may have been variability in the assessment of outcomes by
investigators. However, incomplete information in patient
records resulting in missing data for some variables was not
an important issue, as it was rather low ( 7%) in all cases
except one (tests used for diagnosis: 13.7% unknown). A
further potential limitation is the possibility of different
treatment approaches between hospitals, which may have an
impact on the generalization of the study results.
This large Europe-wide study provides important current
data to characterize the population of patients with cSSTI. The
ﬁndings reveal the heterogeneity that exists in patients with
cSSTI and in clinical management patterns, providing evidence
of a high requirement for initial antibiotic treatment modiﬁ-
cation with some commonly used initial antibiotic regimens
and suggesting reassessment of optimal management regimens
of hospitalized cSSTI patients. For example, patients with co-
morbidities, compared with those without, are associated
with a higher incidence of initial treatment modiﬁcation,
poorer clinical outcomes and signiﬁcantly increased use of
resources, such as longer time to clinical stability and longer
hospital stay. These data highlight the potential need for
reassessment of treatment regimens for this vulnerable
patient group and the potential need for new cSSTI treat-
ments. Data from REACH are likely to provide the founda-
tions for such a reassessment.
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